Cross-cohort meta-analysis reveals conserved gut microbiome signatures of insomniaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether insomnia has a conserved gut microbiome signature that holds across independent human cohorts. Researchers ran a cross-cohort meta-analysis of five public human fecal 16S rRNA case-control datasets. All raw sequencing reads were reprocessed through one unified QIIME2 pipeline, with DADA2 denoising and SILVA 138.1 taxonomy, to reduce technical and cohort-specific noise. They combined four differential-abundance methods (MaAsLin2, db-RDA, Boruta, LEfSe) and predicted function with PICRUSt2, adjusting for age, study location, and cohort.
Who was studied?
The pooled sample was 468 adults from five human case-control cohorts: 304 controls and 164 people with insomnia. All samples were human fecal 16S rRNA gene sequences. The original cohorts excluded people actively using sleep medications or major psychotropic drugs at the time of stool sampling. Samples with fewer than 10,000 retained reads were dropped. Analyses controlled for age, study location, and cohort, with permutations constrained within cohorts.
What were the most important findings?
Insomnia showed a significantly higher Shannon diversity than controls (p=0.003), a direction consistent across all five cohorts. The community group effect stayed significant after covariate adjustment (PERMANOVA p=0.001), with a phylum shift in Bacillota and Bacteroidota (p=0.03). Eight taxa were conserved across all four statistical methods. Five insomnia-enriched genera included the Burkholderia-Caballeronia-Paraburkholderia (BCP) complex and the Ruminococcus gnavus group (each p less than 0.05). Functional analysis flagged 151 robust KOs (31 enriched, 120 depleted in insomnia). The BCP complex was the central hub, contributing to all 12 disease-enriched KOs and 52.4 percent of significant combined KOs.
What are the greatest implications of this study?
The results suggest insomnia carries a reproducible, pathway-specific gut signature rather than broad dysbiosis. Functional remodeling was concentrated in a few anaerobe-associated taxa, touching redox balance, fermentation, and short-chain fatty acid-related metabolism. The authors caution that PICRUSt2 infers metabolic potential from 16S data, not measured activity, so these functions are hypothesis-generating. The BCP complex is largely an environmental organism, so its gut detection may reflect context-dependent expansion. Causal links to sleep need metagenomic, metabolomic, and immune validation, and unmeasured medication effects cannot be excluded.